Navicare Biotech Co., Ltd. (8472) AI Stock Analysis

Navicare Biotech Co., Ltd.

(TPEx:8472)

Select Model

Rating:40Underperform

Price Target:TWD 47.00▼(-11.15% Downside)

Action:initiatedcoverage

Date:11/10/26

The score is primarily constrained by weak financial performance, including persistent losses, margin deterioration, leverage, and negative cash flow. Technical conditions are also unfavorable, while the negative P/E provides little valuation support. The calculated weighted score is 39.95, rounded to 40.

Positive Factors

Revenue ReboundThe 2025 revenue rebound indicates that demand or commercial execution improved after the prior-year contraction. If maintained, stronger sales can improve operating leverage, support investment in the business, and provide a foundation for restoring profitability over the next several quarters.

Negative Factors

Persistent UnprofitabilityPersistent net and operating losses indicate that the business model has not yet converted revenue into sustainable earnings. Continued negative margins can consume capital, constrain reinvestment, and leave results vulnerable if revenue growth or cost improvements fail to persist.

Navicare Biotech Co., Ltd. (8472) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 1.03B
Dividend Yield: ―
Average Volume (3M): 22.68K
Price to Earnings (P/E): -70.1
Beta (1Y): 0.38
Revenue Growth: 19.68%
EPS Growth: 71.10%
Country: TW
Employees: 80
Sector: General
Sector Strength: 55
Industry: Specialty Retail

Navicare Biotech Co., Ltd. Business Overview & Revenue Model

Company Description

Navicare Biotech Co., Ltd. is a Taiwanese enterprise that specializes in offering digital commerce and marketing solutions. The company operates a comprehensive online platform designed to showcase information for a diverse range of vendors. This dig...

Navicare Biotech Co., Ltd. Financial Statement Overview

Summary

Financial performance is weak despite 41.8% revenue growth and a substantially narrower loss. Negative profitability, falling gross margin, rising leverage, and negative operating and free cash flow outweigh the improvements.

Income Statement

28Negative

Balance Sheet

43Neutral

Cash Flow

24Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Mar 2023	Dec 2021
Income Statement
Total Revenue	505.82M	478.07M	337.03M	388.50M	331.55M	305.28M
Gross Profit	181.10M	172.16M	211.87M	281.82M	280.10M	283.92M
EBITDA	-4.42M	-15.09M	-54.05M	-46.75M	-81.95M	22.46M
Net Income	-11.41M	-23.27M	-78.46M	-51.83M	-82.68M	10.77M
Balance Sheet
Total Assets	994.20M	1.05B	999.54M	1.18B	1.21B	1.05B
Cash, Cash Equivalents and Short-Term Investments	165.13M	230.31M	99.12M	141.01M	242.88M	658.58M
Total Debt	318.39M	327.47M	260.97M	248.84M	232.22M	13.26M
Total Liabilities	735.35M	779.12M	714.47M	818.89M	796.38M	521.48M
Stockholders Equity	258.85M	270.50M	285.07M	363.53M	415.36M	527.27M
Cash Flow
Free Cash Flow	-25.28M	-4.12M	-72.22M	-145.37M	-474.62M	-74.47M
Operating Cash Flow	-24.43M	-3.17M	-63.49M	-108.19M	-68.41M	-68.70M
Investing Cash Flow	-80.43M	8.65M	49.10M	68.92M	-157.56M	70.60M
Financing Cash Flow	-24.44M	74.59M	7.07M	10.17M	205.06M	-49.52M

Navicare Biotech Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:8472 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4171	40Underperform	TWD 896.99M	-40.49	―	―	11.99%	84.94%
TW:8472	40Underperform	TWD 853.98M	-70.14	―	―	19.68%	71.10%

* General Sector Average

Performance Comparison

TW:8472 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:8472	Navicare Biotech Co., Ltd.	52.90	-21.60	-28.99%
TW:4171	GeneReach Biotechnology Corp.	15.50	-4.55	-22.69%
TW:6539	DV Biomed Co., Ltd.	36.20	-17.15	-32.15%
TW:6850	Bioptic Inc.	27.65	-14.23	-33.97%
TW:6879	Tci Gene Inc.	35.50	-3.65	-9.32%
TW:7725	LabTurbo Biotech Corporation	21.00	-1.81	-7.93%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Navicare Biotech Co., Ltd. AI Stock Analysis